Effect of a Natural Source Supplementation on Muscle Mass
Primary Purpose
Muscle Disuse Atrophy, Nutrition, Healthy
Status
Completed
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Single leg immobilization
Sponsored by
About this trial
This is an interventional basic science trial for Muscle Disuse Atrophy focused on measuring Skeletal muscle, Supplementation, Disuse, Single-leg immobilization
Eligibility Criteria
Inclusion Criteria:
- Men, between the ages of 20-25 years (inclusive).
- Willing and able to provide informed consent.
- Be in general good health, non-smoking.
- Body mass index (BMI) between 20-35kg/m2.
- Agree to not consume eggs for the duration of the study.
Exclusion Criteria:
- Use of tobacco related products.
- Veganism or vegetarianism.
- Subject has any concurrent medical, orthopedic, or psychiatric condition that, in the opinion of the investigator, would compromise his/her ability to comply with the study requirements.
- History of cancer within the last 5 years, except basal cell carcinoma, non-squamous skin carcinoma, prostate cancer or carcinoma in situ with no significant progression over the past 2 years.
- Significant orthopedic, cardiovascular, pulmonary, renal, liver, infectious disease, immune disorder (requiring ongoing medical care), or metabolic/endocrine disorder (e.g. diabetes, high cholesterol, elevated fasting blood sugar) or other disease that would preclude oral protein supplement ingestion and/or assessment of safety and study objectives.
- Any cachexia-related condition (e.g. relating to cancer, tuberculosis or human immunodeficiency virus infection and acquired immune deficiency syndrome) or any genetic muscle diseases or disorders.
- Current illness with could interfere with the study (e.g. prolonged severe diarrhea, regurgitation, difficulty swallowing).
- Subject participated in a study of an investigational product less than 60 days or 5 half-lives of the investigational product, whichever is longer, before enrollment in this study.
- Hypersensitivity to any of the components of the test product.
- Excessive alcohol consumption (>21 standard drinks/week, e.g. 18oz glass of 5% beer - 1.5 standard drinks, a 750ml bottle of 12% wine = 5 standard drinks).
- Known sensitivity or allergy to amino acids or any ingredient in the test formulations. 12) Prior gastrointestinal bypass surgery (Lapband, etc.), irritable bowel disease or irritable bowel syndrome.
- History of bleeding diathesis, platelet or coagulation disorders, or antiplatelet/anti-coagulation therapy (up to 81 mg of baby aspirin per day taken as a prophylactic is permitted).
- Personal or family history of clotting disorder or deep vein thrombosis. Deep vein thrombosis is a serious, and potentially lethal, medical condition, therefore, it is imperative if you have personal or family history it is disclosed this to the research staff.
- Concomitant use of corticosteroids, testosterone replacement therapy (ingestion, injection, or transdermal), any anabolic steroid, creatine, whey protein supplements, casein or branched-chain amino acids (BCAAs) within 45 days prior to screening.
Sites / Locations
- Exercise Metabolism Research Laboratory, McMaster Univeristy
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Fortetropin
Placebo
Arm Description
Foretetropin, which is non-thermal pasteurized, freeze-dried fertilized egg yolk, per day
Cheese powder, which is isonitrogenous, isoenergetic, and macronutrient-matched with Fortetropin
Outcomes
Primary Outcome Measures
Vastus lateralis cross sectional area
Changes in vastus lateralis cross sectional area (CSA) by ultrasonography.
Single fiber cross sectional area
Fiber type dependent single fiber CSA analyzed by immunohistochemistry
Fat-and-bone free-mass
Fat-and-bone free-mass using DXA.
Secondary Outcome Measures
Myostatin level in plasma
Changes in Myostatin circulation level in plasma.
Leg strength
Changes in isometric muscle strength using Biodex
Basic metabolic panel and liver enzyme
Changes in Basic metabolic panel and liver enzyme (ALT and AST) in plasma
Myostatin positive satellite cells
Changes in the number of myostatin positive satellite cells.
Gastrointestinal response to ingestion of the supplement
Assessment of gastrointestinal response to ingestion of the supplement using Likert scale questionnaire. The minimum (best) value is 1 and maximum (worst) value is 10.
Full Information
NCT ID
NCT05369026
First Posted
May 3, 2022
Last Updated
May 5, 2022
Sponsor
McMaster University
Collaborators
Myos Corporation
1. Study Identification
Unique Protocol Identification Number
NCT05369026
Brief Title
Effect of a Natural Source Supplementation on Muscle Mass
Official Title
Effect of Fortetropin Supplementation in Young Men During Muscle Disuse
Study Type
Interventional
2. Study Status
Record Verification Date
May 2022
Overall Recruitment Status
Completed
Study Start Date
January 1, 2020 (Actual)
Primary Completion Date
March 25, 2022 (Actual)
Study Completion Date
March 25, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
McMaster University
Collaborators
Myos Corporation
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Periods of muscle disuse are commonly experienced in young and elderly individuals as a result of short-term hospitalization or leg casting after injury. Periods of immobilization result in a profound loss of muscle mass and strength. This loss of muscle mass can have negative effects on health and the ability to carry out activities of daily living. Thus, it is very important to try to maintain muscle mass during muscle disuse. Recent research suggests that Fortetropin, which is an all-natural protein-fat complex made from fertilized hen egg yolks, can enhance muscle mass and strength with weightlifting in young men. In this study, we aim to investigate the safety and tolerability of Fortetropin and whether Fortetropin supplementation can reduce or prevent the loss of muscle mass during single-leg immobilization while you are wearing a knee brace. To make this decision, we require a study to compare Fortetropin to a placebo (something that contains the same amount of protein and energy as Fortetropin). The findings from this study will help us understand if Fortetropin supplementation is safe, tolerable, and can be used to slow muscle loss in people who undergo periods of muscle disuse (i.e. surgery, sickness).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Muscle Disuse Atrophy, Nutrition, Healthy
Keywords
Skeletal muscle, Supplementation, Disuse, Single-leg immobilization
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
24 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Fortetropin
Arm Type
Experimental
Arm Description
Foretetropin, which is non-thermal pasteurized, freeze-dried fertilized egg yolk, per day
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Cheese powder, which is isonitrogenous, isoenergetic, and macronutrient-matched with Fortetropin
Intervention Type
Other
Intervention Name(s)
Single leg immobilization
Intervention Description
2 weeks of single-leg immobilization
Primary Outcome Measure Information:
Title
Vastus lateralis cross sectional area
Description
Changes in vastus lateralis cross sectional area (CSA) by ultrasonography.
Time Frame
Baseline (Day 0), pre-immobilization (Day 14), post-immobilization (Day 28), post-recovery (Day 42)
Title
Single fiber cross sectional area
Description
Fiber type dependent single fiber CSA analyzed by immunohistochemistry
Time Frame
Baseline (Day 0), pre-immobilization (Day 14), post-immobilization (Day 28), post-recovery (Day 42)
Title
Fat-and-bone free-mass
Description
Fat-and-bone free-mass using DXA.
Time Frame
Baseline (Day 0), pre-immobilization (Day 14), post-immobilization (Day 28), post-recovery (Day 42)
Secondary Outcome Measure Information:
Title
Myostatin level in plasma
Description
Changes in Myostatin circulation level in plasma.
Time Frame
Baseline (Day 0) and Post-recovery (Day 42)
Title
Leg strength
Description
Changes in isometric muscle strength using Biodex
Time Frame
Baseline (Day 0), pre-immobilization (Day 14), post-immobilization (Day 28), post-recovery (Day 42)
Title
Basic metabolic panel and liver enzyme
Description
Changes in Basic metabolic panel and liver enzyme (ALT and AST) in plasma
Time Frame
Baseline (Day 0), post-recovery (Day 42)
Title
Myostatin positive satellite cells
Description
Changes in the number of myostatin positive satellite cells.
Time Frame
Baseline (Day 0), pre-immobilization (Day 14), post-immobilization (Day 28), post-recovery (Day 42)
Title
Gastrointestinal response to ingestion of the supplement
Description
Assessment of gastrointestinal response to ingestion of the supplement using Likert scale questionnaire. The minimum (best) value is 1 and maximum (worst) value is 10.
Time Frame
Pre-immobilization (Day 14), post-immobilization (Day 28), post-recovery (Day 42)
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
25 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Men, between the ages of 20-25 years (inclusive).
Willing and able to provide informed consent.
Be in general good health, non-smoking.
Body mass index (BMI) between 20-35kg/m2.
Agree to not consume eggs for the duration of the study.
Exclusion Criteria:
Use of tobacco related products.
Veganism or vegetarianism.
Subject has any concurrent medical, orthopedic, or psychiatric condition that, in the opinion of the investigator, would compromise his/her ability to comply with the study requirements.
History of cancer within the last 5 years, except basal cell carcinoma, non-squamous skin carcinoma, prostate cancer or carcinoma in situ with no significant progression over the past 2 years.
Significant orthopedic, cardiovascular, pulmonary, renal, liver, infectious disease, immune disorder (requiring ongoing medical care), or metabolic/endocrine disorder (e.g. diabetes, high cholesterol, elevated fasting blood sugar) or other disease that would preclude oral protein supplement ingestion and/or assessment of safety and study objectives.
Any cachexia-related condition (e.g. relating to cancer, tuberculosis or human immunodeficiency virus infection and acquired immune deficiency syndrome) or any genetic muscle diseases or disorders.
Current illness with could interfere with the study (e.g. prolonged severe diarrhea, regurgitation, difficulty swallowing).
Subject participated in a study of an investigational product less than 60 days or 5 half-lives of the investigational product, whichever is longer, before enrollment in this study.
Hypersensitivity to any of the components of the test product.
Excessive alcohol consumption (>21 standard drinks/week, e.g. 18oz glass of 5% beer - 1.5 standard drinks, a 750ml bottle of 12% wine = 5 standard drinks).
Known sensitivity or allergy to amino acids or any ingredient in the test formulations. 12) Prior gastrointestinal bypass surgery (Lapband, etc.), irritable bowel disease or irritable bowel syndrome.
History of bleeding diathesis, platelet or coagulation disorders, or antiplatelet/anti-coagulation therapy (up to 81 mg of baby aspirin per day taken as a prophylactic is permitted).
Personal or family history of clotting disorder or deep vein thrombosis. Deep vein thrombosis is a serious, and potentially lethal, medical condition, therefore, it is imperative if you have personal or family history it is disclosed this to the research staff.
Concomitant use of corticosteroids, testosterone replacement therapy (ingestion, injection, or transdermal), any anabolic steroid, creatine, whey protein supplements, casein or branched-chain amino acids (BCAAs) within 45 days prior to screening.
Facility Information:
Facility Name
Exercise Metabolism Research Laboratory, McMaster Univeristy
City
Hamilton
State/Province
Ontario
ZIP/Postal Code
L8S 4K1
Country
Canada
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Effect of a Natural Source Supplementation on Muscle Mass
We'll reach out to this number within 24 hrs